Welcome to our dedicated page for Prime Medicine SEC filings (Ticker: PRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prime Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prime Medicine's regulatory disclosures and financial reporting.
Prime Medicine, Inc. reported that an arbitration tribunal issued a final award resolving its dispute with Beam Therapeutics over their 2019 Collaboration and License Agreement. The tribunal declared that PM647, Prime Medicine’s development candidate for treating Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine’s contractual field and that the company did not breach the agreement. As a result, the tribunal denied Beam’s requests for damages and injunctive relief based on its breach allegations. The tribunal also denied the remaining claims brought by both Beam and Prime Medicine.
Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. Following this grant, he holds options on 75,000 shares.
The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders, provided he remains in continuous service with the company through that vesting date. This is a compensation-related, non‑market transaction.
Prime Medicine, Inc. director Jeffrey D. Marrazzo reported receiving a grant of stock options on June 5, 2026. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, held directly.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, provided he continues serving the company through that date. The options expire on June 5, 2036, and following this grant he holds 75,000 derivative securities of this type.
Prime Medicine director and 10% owner Robert Nelsen received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, all 75,000 underlying shares vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, assuming he continues to provide service to the company through that vesting date. This is a compensation-related award, not an open-market purchase or sale.
Prime Medicine director Kelly Michael Aaron received a new stock option grant that could convert into common shares in the future. The award covers 75,000 shares of common stock at an exercise price of $3.06 per share and expires on June 5, 2036. According to the terms, the option vests in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual stockholder meeting, as long as Aaron continues serving the company through that vesting date. After this grant, Aaron holds stock options for 75,000 underlying shares directly.
Prime Medicine, Inc. reported that director Kaye I Foster-Cheek received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036.
The 75,000 options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, subject to Foster-Cheek’s continuous service. Following this grant, the filing shows holdings of 75,000 derivative securities, with no open‑market buys or sells reported.
Prime Medicine, Inc. director Wendy Chung reported receiving a grant of stock options. The award covers 75,000 options to buy Prime Medicine common stock at an exercise price of $3.06 per share, with all 75,000 options shown as held after this grant.
The options vest in full on the earlier of June 5, 2027 or the date of the next annual meeting of stockholders, as long as Chung continues to provide service to the company through that vesting date. The options expire on June 5, 2036 if not exercised.
Prime Medicine, Inc. director Thomas Cahill received a grant of stock options covering 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. They vest in full on the earlier of June 5, 2027 or the next annual stockholder meeting, assuming continuous service, leaving Cahill with 75,000 derivative shares after this award.
Prime Medicine, Inc. held its 2026 annual stockholder meeting on June 5, 2026 via live webcast. A quorum was established with 140,384,724 shares present or represented by proxy out of 180,615,889 shares of common stock entitled to vote as of the April 9, 2026 record date.
Stockholders elected Michael Kelly and David Schenkein, M.D. as Class I directors to serve until the 2029 annual meeting, with 107,059,058 and 87,522,409 votes "for," respectively. They also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 139,989,201 votes in favor.